Labopharm Inc. says an additional Phase 3 clinical trial may be needed to satisfy U.S. Food and Drug Administration in an approval application for its once-daily painkiller tramadol.

The company said a recent meeting with the agency "was productive" and the statistical analysis needed for approval "has been clearly delineated."